Danaher Co. (NYSE:DHR) Shares Sold by Lmcg Investments LLC

Lmcg Investments LLC reduced its stake in Danaher Co. (NYSE:DHR) by 1.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 93,646 shares of the conglomerate’s stock after selling 1,451 shares during the quarter. Danaher accounts for 1.3% of Lmcg Investments LLC’s portfolio, making the stock its 13th largest position. Lmcg Investments LLC’s holdings in Danaher were worth $21,496,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher in the 3rd quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the 3rd quarter valued at approximately $40,000. FSA Wealth Management LLC acquired a new position in shares of Danaher in the third quarter worth $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter valued at $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.4 %

Shares of Danaher stock opened at $238.41 on Tuesday. The company has a market cap of $172.20 billion, a P/E ratio of 45.50, a PEG ratio of 4.30 and a beta of 0.83. The firm has a fifty day moving average of $234.85 and a two-hundred day moving average of $253.51. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a one year low of $222.53 and a one year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm’s revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 earnings per share. On average, analysts forecast that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Citigroup dropped their target price on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. KeyCorp lifted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. TD Cowen increased their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Finally, Raymond James decreased their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.